Cost-effectiveness analysis of colonoscopy for screening colorectal cancer in Indonesia using Markov Model 10.55131/jphd/2025/230314
Article Sidebar
Main Article Content
Abstract
Colorectal cancer (CRC) is one of the top three diagnosed cancers worldwide and the second leading cause of cancer-related deaths, imposing a significant economic burden. In this context, early detection is crucial for effective management. The primary detection method particularly for high-risk individuals is colonoscopy but screening has not been widely adopted and the participation rate and the colonoscopy screening compliance rate were low. Pharmacoeconomic investigations are essential for evaluating the costs and effectiveness of colonoscopy screening for colorectal cancer. Therefore, this research aimed to conduct a cost-effectiveness analysis using a Markov model for a cohort of 100,000 adults aged 45 to compare the outcomes of screened and unscreened scenarios. The Markov model developed in this study consists of three main stages: the health stage, the colorectal cancer stage, and the death stage. The parameters used in this study include the probabilities at each stage, costs, the sensitivity and specificity of colonoscopy, utilities at each stage, and the discount rate. One-way and probabilistic sensitivity analyses were conducted to address uncertainty. Meanwhile, the Incremental Cost-Effectiveness Ratio (ICER) of screening colonoscopy compared to no screening for adult patients was found to be cost-effective and valued at USD 6,191.15/QALY (Quality-adjusted Life Year). This value was significantly below the Cost-Effectiveness Threshold (CET) assumed to be USD 14,759.10. Based on the cost-effectiveness acceptability curve at a willingness to pay (WTP) threshold of USD 5,500, the probability of being cost-effective for colorectal cancer screening increased and consistently reached 100% at a WTP level of USD 9,000. Colonoscopy screening was cost-effective when analyzed using the Markov model, as suggested by ICER value exceeding three times the Gross Domestic Product (GDP) of Indonesia. Future research could explore alternative interventions, such as biennial colonoscopy, and compare the result with other screening methods.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
References
Ramdzan AR, Manaf MRA, Aizuddin AN, Latiff ZA, Teik KW, Ch’ng G, et al. Cost-Effectiveness of Colorectal Cancer Genetic Testing. Int. J. Environ. Res. Public Health. 2021;18: 1-17. doi: 10.3390/ijerph 18168330.
CDC. Colorectal Cancer [document on the Internet]. USA: U.S. Centers for Disease Control and Prevention.; 2023 [cited 2024 June 10]. Available from: https://www.cdc.gov/colorectal-cancer/site.html.
Chen C, Stock C, Hoffmeister M, Brenner H. Optimal Age for Screening Colonoscopy: a Modelling Study. Gastrointest. Endosc. 2019; 89(5): 1017-1025. doi: 10.1016/ j.gie.2018.12.021.
Menteri Kesehatan Republik Indonesia. Pedoman Nasional Pelayanan Kedokteran Tata Laksana Kanker Kolorektal. Keputusan Menteri Kesehatan Republik Indonesia Nomor HK.01.07/ MENKES/406/2018; 2018.
Abdullah M, Nufus H, Syam AF, Rani AA. The Use of Immunochemical Fecal Occult Blood Test as Colorectal Cancer Screening Tool in Asymptomatic Population in Indonesia. INA JGHE. 2014;15(1): 15-19. doi: https://doi.org/10.24871/ 151201415-9.
Rees CJ, Bevan R, Zimmermann-Fraedrich K, Rutter MD, Rex D, Dekker E, et al. Expert Opinions and Scientific Evidence for Colonoscopy Key Performance Indicators. Gut. 2016;65: 2045-2060. doi: https:// doi.org/10.1136/gutjnl-2016-312043.
Purnomo HD, Permatadewi CO, Prasetyo A, Indiarso D, Hutami HT, Puspasari D, et al. Colorectal cancer screening in Semarang, Indonesia: A multicenter primary health care based study. PloS ONE. 2023;18(1). doi: https://doi.org/10.1371/journal.pone.0279570.
Anh NQ, Ha NT. Does National Colorectal Cancer Screening Program Represent Good Value for Money? Results from a Return-on-Investment Model in Vietnam. Health Serv. Insights. 2021;14: 1-10. doi: 10.1177/11786329211017418.
Zhou Q, Li H, Li Y, Gu Y, Liang Y, Liu H, et al. Cost-effectiveness analysis of different screening strategies for colorectal cancer in Guangzhou, Southern China: a Markov Simulation Analysis Based on Natural Community Scrreening Results. BMJ Open. 2021;11: 1-9. doi: 10.1136/bmjopen-2021-049581.
Bradley SH, Nicholson BD, Funston G. Interpreting Negative Test Results When Assessing Cancer Risk in General Practice. BJGP. 2021; 71(708): 298-299. doi: 10.3399/bjgp21X716189.
Wang ZH, Gao QY, Fang JY. Repeat Colonoscopy Every 10 Years or Single Colonoscopy for Colorectal Neoplasm Screening in Average-risk Chinese: A Cost-effectiveness Analysis. APJCP. 2012;13: 1761–1766. doi: 10.7314/apjcp.2012.13.5. 1761.
Lee JA, Chang Y, Kim Y, Park DI, Park SK, Park HY, et al. Colonoscopic Screening and Risk of All-Cause and Colorectal Cancer Mortality in Young and Older Individuals. Cancer Res Treat. 2023;55: 618–625. doi: 10.4143/crt. 2022.852.
Pemerintah Kota Tangerang Selatan. Tarif Layanan Badan Layanan Umum Daerah Rumah Sakit Umum Kota Tangerang Selatan. Peraturan Wali Kota Tangerang Selatan Nomor 5 Tahun 2023; 2023.
Amalia AR, Herowati R, Andayani TM. Real Cost Analysis and Compatibility with INA-CBG’s Rates in Colorectal Cancer Patients in Hospital of Surakarta in 2018. Jurnal Farmasi Indonesia. 2021;18: 121-132. doi: 10.1136/bmjopen-2021-049581.
Senore C, Hassan C, Regge D, Pagano E, Iussich G, Correale L, et al. Cost-effectiveness of colorectal cancer screening programmes using sigmoidoscopy and immunochemical faecal occult blood test. Cancer Res Treat. 2019; 26(2): 76-83. doi: 10.4143/crt.2022.852.
Hassan C, Giulo ED, Marmo R, Zullo A, Annibale B. Appropriateness of the Indication for Colonoscopy: Systematic Review and Meta-analysis. J Gastrointestin Liver Dis. 2011; 20(3): 279-286.
Kristin E, Endarti D, Khoe LC, Taroeno-Hariadi KW, Trijayanti C, Armansyah A, et al. Economic Evaluation of Adding Bevacizumab to Chemotherapy for Metastatic Colorectal Cancer (mCRC) Patients in Indonesia. APJCP. 2021;22: 1921-1926. doi: https://doi.org/10.31557/ APJCP.2021.22.6.1921.
Schliemann D, Ramanathan K, Matovu N, O’Neill C, Kee F, Su TT, et al. The implementation of colorectal cancer screening interventions in low-and middle-income countries: a scoping review. BMC Cancer. 2021;21: 1-16. doi: https://doi.org/10.1186/s12885-021-08809-1.
Antara GER. Colonoscopy surveillance of colorectal cancer post-surgery in Sanglah General Hospital, Bali, Indonesia: a descriptive study. Intisari Sains Medis. 2021;12(3): 732-734. doi: https://doi.org/10.15562/ism.v12i3.1168.
Javadinasab H, Daroudi R, Salimzadeh H, Delavari A, Vezvaie P, Malekzadeh R. Cost-effectiveness of screening colonoscopy in Iranian high-risk population. 2017;20(9): 564-571.
Badan Pusat Statistik. Ekonomi Indonesia Triwulan IV-2023 Tumbuh 5,04 Persen (y-on-y) [document on the Internet]. Indonesia: Badan Pusat Statistik; 2023 [cited 2024 June 10]. Available form: https://www.bps. go.id/id/pressrelease/2024/02/05/2379/ekonomi-indonesia-triwulan-iv-2023tumbuh-5-04-persen--y-on-y-.html.
Phisalprapa P, Supakankunti S, Chaiyakunapruk N. Cost-effectiveness and budget impact analyses of colorectal cancer screenings in a low- and middle-income country: example from Thailand. J. Med. Econ. 2019;22: 1351–1361. doi: 10.1080/13696998. 2019.1674065.
Khalili F, Najafi B, Mansour-Ghanaei F, Yousefi M, Abdollahzad H, Motlagh A. Cost-Effectiveness Analysis of Colorectal Cancer Screening: A Systematic Review. Risk Management and Healthcare Policy. 2020;13: 1499-1512. doi: 10.2147/RMHP.S262171
Puttelaar R, Lima PN, Knudsen AB, Rutter CM, Kuntz KM, Jonge L, et al. Effectiveness and Cost-Effectiveness of Colorectal Cancer Screening with a Blood Test That Meets the Centers for Medicare & Medicaid Services Coverage Decision. Gastroenterology. 2024;167(2): 368-377. doi: 10.1053/ j.gastro.2024. 02.012.
